In the Moment

First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple cancers: “Our study reported an overall response rate of 37 percent for RET-driven cancers, with responses of 45 percent for non-small cell lung cancer and 32 percent for medullary thyroid.”

Advertisements